诺和诺德Novo Nordisk (NVO) 2022年年度报告「NYSE」.pdf

1、AnnualReport 2022Erik Hageman(far right)is one of Denmarks longest-living people with type 1 diabetes,pictured here with his son Lars,who also has type 1 diabetes,and his grandchildren(from the left)Clara,Emilie and HolgerNovo Nordisk A/S Novo Alle 1,2880 Bagsvrd,Denmark CVR no.24256790In 2022,we re

2、duced CO2 emissions from operations and transportation by 29%compared to 2019Read more on page 13Management reviewConsolidated statements and additional informationPAGE 03-51PAGE 52-10303 Introducing Novo Nordisk04 Letter from the Chair and the CEO06 Novo Nordisk at a glance07 Our value creation08 P

3、erformance highlights10 Strategic Aspirations11 Purpose and sustainability(ESG)27 Innovation and therapeutic focus33 Commercial execution36 Financials44 Key risks45 Risk management 47 Management48 Board of Directors51 Executive Management54 Consolidated financial statements54 Income statement and St

4、atement of comprehensive income55 Cash flow statement 56 Balance sheet 57 Equity statement58 Notes to the consolidated financial statements89 Consolidated ESG statement 89 Statement of Environmental,Social and Governance(ESG)performance90 Notes to the consolidated ESG statement98 Statements and Audi

5、tors Reports98 Statement by the Board of Directors and Executive Management99 Independent Auditors Report on the Financial Statement101 Independent Assurance Report on the ESG statement102 Additional information102 More information103 Product overviewIn 2022,close to 5.5 million patients were reache

6、d through our access and affordability initiativesRead more on page 15Novo Nordisk Annual Report 20222Contents Introducing Novo Nordisk Strategic Aspirations Key risks Management Consolidated statements Additional information04 Letter from the Chair and the CEO06 Novo Nordisk at a glance07 Our value